Vemurafenib-associated neutrophilic panniculitis in a patient with metastatic amelanotic melanoma presenting as cancer of unknown primary origin | Zendy

YuChing Weng | Zendy; ChienShan Chiu | Zendy; TsengHsi Lin | Zendy; JuiLung Shen | Zendy; Chii-Shuenn Yang | Zendy; Joe-Bin Chen | Zendy

Open Access

Vemurafenib-associated neutrophilic panniculitis in a patient with metastatic amelanotic melanoma presenting as cancer of unknown primary origin

Author(s) -

YuChing Weng,

ChienShan Chiu,

TsengHsi Lin,

JuiLung Shen,

Chii-Shuenn Yang,

Joe-Bin Chen

Publication year - 2015

Publication title -

dermatologica sinica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.604

H-Index - 17

eISSN - 2223-330X

pISSN - 1027-8117

DOI - 10.1016/j.dsi.2015.08.002

Subject(s) - vemurafenib , medicine , melanoma , v600e , metastatic melanoma , dermatology , amelanotic melanoma , cancer , oncology , adverse effect , mutation , cancer research , gene , biochemistry , chemistry

The treatment of metastatic melanoma is challenging. BRAF gene mutation is found in 40–60% of melanoma cases, the most common being the V600E mutation. Vemurafenib was approved by the Food and Drug Administration in 2011 as target therapy for the treatment with BRAF V600 mutation-positive metastatic melanoma. We report a case of metastatic amelanotic melanoma with unknown primary cancer as the initial presentation. The patient presented with neutrophilic septal panniculitis 1 week after vemurafenib treatment, which is a rare cutaneous toxicity of BRAF inhibitor. We also review the current literature on management of BRAF inhibitor-related adverse skin effects

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research